# SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

Source: https://onco.cc/trials/nct07551635/  
OnCo record `nct07551635` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Dana-Farber Cancer Institute, not yet recruiting.

## Summary

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC is a phase 2, interventional study registered as NCT07551635 by Dana-Farber Cancer Institute, with a registry enrolment figure of 20 participants, started 2026-09-04 and due to reach its primary completion in 2028-01-31. Interventions recorded: FHD-286. Conditions listed: Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed extensive stage SCLC with documented disease progression or recurrence after prior platinum-based therapy with or without checkpoint inhibitor". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07551635
- Phase: 2
- Setting: A Phase 2 Study of SMARCA4/2 Inhibitor (FHD-286) for POU2F3-Positive Small-Cell Lung Cancer
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07551635: https://clinicaltrials.gov/study/NCT07551635

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Foghorn Therapeutics](https://onco.cc/companies/foghorn-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07551635.json